{"id":2808,"date":"2026-08-24T22:19:41","date_gmt":"2026-08-24T22:19:41","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=2808"},"modified":"2026-08-24T22:19:42","modified_gmt":"2026-08-24T22:19:42","slug":"buy-cjc-1295-ipamorelin-ghrp-2-blend-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-cjc-1295-ipamorelin-ghrp-2-blend-in-switzerland\/","title":{"rendered":"CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9MG)"},"content":{"rendered":"

What Is the CJC-1295 & Ipamorelin & GHRP-2 Blend and Why Buy It for Research?<\/strong><\/h2>\n

Buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland for research into growth hormone axis signaling, synergistic GH release, and metabolic regulation. Specifically, this 9mg research formulation combines three complementary growth hormone secretagogues in a single pre-mixed lyophilized vial: CJC-1295 (Mod GRF 1-29, 3mg), Ipamorelin (3mg), and GHRP-2 (3mg). This blend pairs a growth hormone-releasing hormone (GHRH) analog with two mechanistically distinct ghrelin receptor agonists to probe convergent pathways in the GH-IGF-1 axis.<\/p>\n

CJC-1295 (without DAC, also known as Modified GRF 1-29) is a synthetic 29-amino acid peptide analog of GHRH that activates the GHRH receptor on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that engages the GHS-R1a receptor through Gq\/11-coupled signaling, mobilizing intracellular calcium to trigger GH granule release. GHRP-2 (Pralmorelin) is a synthetic hexapeptide that also activates GHS-R1a but engages a broader signaling response, including hypothalamic circuits that suppress somatostatin and stimulate endogenous GHRH secretion. Furthermore, when combined, these three peptides produce synergistic GH release through convergent but mechanistically independent pathways. Moreover, Core Peptides supplies this blend as a lyophilized powder in a 9mg format exclusively for laboratory use. Therefore, researchers seeking to source this combination for their work will find it readily available when they buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland.<\/p>\n

CJC-1295 & Ipamorelin & GHRP-2 Blend Research Overview: Buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland for GH Axis Studies<\/strong><\/h2>\n

Centrally, research into the CJC-1295, Ipamorelin, and GHRP-2 blend has focused on the complementary and synergistic mechanisms of its three components. The foundational observation that GHRH + GHRP produces synergistic GH release was established by Bowers et al. in human subjects, demonstrating that co-administration of GHRH and GHRP produced GH peaks significantly higher than either peptide alone.<\/p>\n

CJC-1295 (Mod GRF 1-29) functions as a GHRH analog that binds to the GHRH receptor (GHRH-R), a G-protein coupled receptor (GPCR) on pituitary somatotrophs. Importantly, the peptide incorporates four strategic amino acid substitutions at positions 2 (Ala to D-Ala), 8 (Asn to Gln), 15 (Gly to Ala), and 27 (Met to Leu), which confer resistance to DPP-IV cleavage and other degradation pathways, extending the biological half-life to approximately 30 minutes. As a result, this binding activates a downstream signaling cascade that results in GH synthesis and release.<\/p>\n

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH\u2082. Specifically, it mimics ghrelin and binds to the ghrelin receptor (GHS-R1a) in the pituitary, thereby selectively stimulating the release of GH. Unlike other GH releasing peptides, ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone, with negligible cortisol or prolactin elevation.<\/p>\n

GHRP-2 (Pralmorelin, KP-102) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH\u2082. In addition to its direct pituitary effects, it acts indirectly on the hypothalamus, stimulating endogenous GHRH release from arcuate nucleus neurons and functionally suppressing somatostatin release from periventricular neurons. Consequently, this dual hypothalamic action creates a permissive environment for maximal GH pulse amplitude.<\/p>\n

When combined, CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release and GHRP-2 amplifies output through hypothalamic effects and suppression of somatostatin. Therefore, the triple combination amplifies GH output through convergent but mechanistically independent pathways. Accordingly, researchers who buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland from Core Peptides can support their investigations into GH axis signaling, synergistic peptide interactions, and metabolic regulation.<\/p>\n

How Does the CJC-1295 & Ipamorelin & GHRP-2 Blend Work in Research?<\/strong><\/h2>\n

Mechanistically, the CJC-1295, Ipamorelin, and GHRP-2 blend operates through three complementary signaling pathways that converge on GH release from pituitary somatotrophs.<\/p>\n

GHRH Receptor Pathway (CJC-1295)<\/strong><\/h3>\n

CJC-1295 activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, driving cAMP\/PKA-mediated GH synthesis and secretion. It functions as a stable and active hGRF1-29 analog with a half-life of approximately 30 minutes. As a result, this binding initiates a downstream signaling cascade that results in GH synthesis and release, with CJC-1295 showing a 4-fold increase in GH area under the curve over a 2-hour period compared with hGRF1-29.<\/p>\n

GHS-R1a Pathway (Ipamorelin)<\/strong><\/h3>\n

Ipamorelin binds GHS-R1a and activates Gq\/11-coupled PLC signaling, generating IP3 and DAG. Consequently, the resulting intracellular calcium mobilization triggers rapid exocytosis of pre-formed GH vesicles. Notably, Ipamorelin’s key distinguishing feature is its failure to significantly stimulate ACTH or cortisol release at GH-effective doses, suggesting preferential activation of specific downstream signaling branches.<\/p>\n

Broad Ghrelin Pathway (GHRP-2)<\/strong><\/h3>\n

GHRP-2 also activates GHS-R1a but engages a broader signaling response. Beyond somatotroph GH release, GHRP-2 activates hypothalamic circuits that suppress somatostatin release and stimulate endogenous GHRH secretion, creating a feed-forward loop. In addition, this broader activation profile may contribute to metabolic effects beyond isolated GH release.<\/p>\n

Synergistic Effects<\/strong><\/h3>\n

The triple combination produces synergistic (not merely additive) GH release. Specifically, CJC-1295 sustains physiologic pulsatile GH secretion while Ipamorelin provides selective GH release and GHRP-2 amplifies output through hypothalamic effects and suppression of somatostatin. Moreover, combining two GHS-R1a agonists (Ipamorelin and GHRP-2) with a GHRH analog (CJC-1295) produces more complete receptor activation through potential differences in receptor binding kinetics, biased agonism profiles, and secondary target engagement.<\/p>\n

Why Is the CJC-1295 & Ipamorelin & GHRP-2 Blend Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study this blend because it represents a well-characterized triple combination of complementary GH secretagogues that enables investigation of synergistic GH release, metabolic regulation, and receptor pharmacology. In fact, this pre-mixed blend offers a practical way to study convergent GH axis signaling without the need to source and reconstitute each compound separately.<\/p>\n

Research has demonstrated the blend’s relevance across multiple domains. For instance, GH pulse amplitude is a key determinant of recovery-relevant downstream effects including IGF-1 elevation, protein synthesis stimulation, lipolysis, and collagen synthesis. Furthermore, research in GH-deficient models demonstrates that pulsatile GH administration is more effective than continuous infusion for promoting lean body mass and reducing adiposity, supporting the value of high-amplitude pulse protocols. Additionally, Ipamorelin’s selective GH release profile with minimal cortisol elevation makes it valuable for studies requiring isolated GH effects. Likewise, GHRP-2’s broader hypothalamic effects provide additional mechanisms for amplifying GH output. Ultimately, researchers who buy CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland gain access to a comprehensive research tool for investigating GH axis signaling, metabolic regulation, and receptor pharmacology.<\/p>\n

CJC-1295 & Ipamorelin & GHRP-2 Blend Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nKey Components<\/th>\n<\/tr>\n<\/thead>\n
GH Axis Signaling<\/td>\nTriple-pathway activation, GHRH\/GHS receptor crosstalk, pulsatile secretion<\/td>\nAll three (complementary pathways)<\/td>\n<\/tr>\n
Metabolic Regulation<\/td>\nIGF-1 elevation, lipolysis, protein synthesis, metabolic homeostasis<\/td>\nAll three (GH-dependent effects)<\/td>\n<\/tr>\n
Receptor Pharmacology<\/td>\nGHRH-R, GHS-R1a binding, biased agonism, receptor binding kinetics<\/td>\nAll three (distinct targets)<\/td>\n<\/tr>\n
Hypothalamic-Pituitary Axis<\/td>\nSomatostatin suppression, endogenous GHRH release, feed-forward amplification<\/td>\nGHRP-2<\/td>\n<\/tr>\n
Selective GH Release<\/td>\nGH-specific effects, minimal cortisol\/prolactin spillover<\/td>\nIpamorelin<\/td>\n<\/tr>\n
Pulsatile GH Secretion<\/td>\nPhysiologic GH patterning, amplitude modulation, pulse dynamics<\/td>\nCJC-1295<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

CJC-1295 & Ipamorelin & GHRP-2 Blend Compared With Related Research Formulations<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Formulation<\/th>\nComponents<\/th>\nResearch Focus<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
CJC-1295 + Ipamorelin + GHRP-2 Blend<\/td>\nCJC-1295 + Ipamorelin + GHRP-2 (1:1:1)<\/td>\nTriple-pathway GH axis, synergistic release, receptor pharmacology<\/td>\nMost comprehensive GH amplification; dual GHS-R1a agonism<\/td>\n<\/tr>\n
CJC-1295 + Ipamorelin Blend<\/td>\nCJC-1295 + Ipamorelin<\/td>\nGH release, metabolic regulation<\/td>\nTwo-peptide blend; selective GH release, minimal cortisol<\/td>\n<\/tr>\n
CJC-1295 + Hexarelin Blend<\/td>\nCJC-1295 + Hexarelin<\/td>\nGH axis, cardioprotection<\/td>\nTwo-peptide blend; Hexarelin adds CD36 cardioprotection<\/td>\n<\/tr>\n
CJC-1295 with DAC<\/td>\nCJC-1295 with Drug Affinity Complex<\/td>\nSustained GH elevation, growth and metabolism<\/td>\nSingle peptide; extended half-life (6-8 days)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, the CJC-1295, Ipamorelin, and GHRP-2 blend differs from other GHRH\/GHS combinations in its triple-pathway approach. On the one hand, the CJC-1295 and Ipamorelin blend provides selective GH release with minimal cortisol elevation. On the other hand, adding GHRP-2 introduces broader hypothalamic effects\u2014including somatostatin suppression and endogenous GHRH stimulation\u2014that further amplify GH output. In contrast, the CJC-1295 and Hexarelin blend adds CD36-mediated cardioprotection, while CJC-1295 with DAC provides sustained elevation rather than pulsatile release.<\/p>\n

Research Applications for the CJC-1295 & Ipamorelin & GHRP-2 Blend in Switzerland<\/strong><\/h2>\n

Scientists have investigated this triple-peptide blend across several research domains:<\/p>\n